Mycophenolate Mofetil Sandoz

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Sandoz, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis by modulating the immune response in adult patients.

GNH USA supplies Mycophenolate Mofetil Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, meeting EU quality standards and shipped under controlled conditions to ensure product integrity.

Mycophenolate Mofetil is used to modulate immune activity in conditions where excessive lymphocyte proliferation is harmful. - Organ transplant rejection: helps prevent acute rejection episodes in kidney, heart and liver transplants. - Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus. - Graft‑versus‑host disease prophylaxis: used in some protocols to lower the incidence of GVHD after hematopoietic stem cell transplantation.

Adverse reactions may occur with Mycophenolate Mofetil therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Headache: transient cranial discomfort. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Leukopenia: reduced white blood cell count. - Anemia: lowered red blood cell levels.

Serious or Rare Side Effects: - Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Bone marrow suppression: pancytopenia requiring medical intervention. - Renal impairment: elevated serum creatinine or reduced glomerular filtration rate. - Hepatotoxicity: abnormal liver enzymes or hepatitis. - Malignancy: increased risk of post‑transplant lymphoproliferative disorders.

Patients receiving Mycophenolate Mofetil should be monitored closely for safety concerns. - Blood counts: perform regular complete blood count to detect leukopenia or anemia. - Renal function: monitor serum creatinine and eGFR periodically. - Live vaccines: avoid administration due to heightened infection risk. - Pregnancy: assess risks and benefits; use only if clearly needed. - Dose adjustments: consider hepatic impairment when titrating therapy. - Store at below 25°C: keep in the original pack, protect from moisture.

Mycophenolate Mofetil can interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid): - Antimetabolites (e.g., azathioprine): additive immunosuppression may increase infection risk. - Live vaccines: concurrent use can lead to severe infection. - Rifampin or other strong inducers: markedly reduce mycophenolate exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase mycophenolate levels. - ACE inhibitors or ARBs: monitor renal function as combined effect can worsen kidney parameters. - Non‑live vaccines: immune response may be attenuated; assess serologic protection.